Publication: Glycoproteomic analysis reveals aberrant expression of complement C9 and fibronectin in the plasma of patients with colorectal cancer
1
Issued Date
2020-09-01
Resource Type
ISSN
22277382
Other identifier(s)
2-s2.0-85092463065
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Proteomes. Vol.8, No.3 (2020)
Suggested Citation
Juthamard Chantaraamporn, Voraratt Champattanachai, Amnart Khongmanee, Chris Verathamjamras, Naiyarat Prasongsook, Kanokwan Mingkwan, Virat Luevisadpibul, Somchai Chutipongtanate, Jisnuson Svasti Glycoproteomic analysis reveals aberrant expression of complement C9 and fibronectin in the plasma of patients with colorectal cancer. Proteomes. Vol.8, No.3 (2020). doi:10.3390/PROTEOMES8030026 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/59881
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Glycoproteomic analysis reveals aberrant expression of complement C9 and fibronectin in the plasma of patients with colorectal cancer
Abstract
© 2020 by the authors. Colorectal cancer (CRC) is a major cause of cancer mortality. Currently used CRC biomarkers provide insufficient sensitivity and specificity; therefore, novel biomarkers are needed to improve the CRC detection. Label-free quantitative proteomics were used to identify and compare glycoproteins, enriched by wheat germ agglutinin, from plasma of CRC patients and age-matched healthy controls. Among189 identified glycoproteins, the levels of 7 and 15 glycoproteins were significantly altered in the non-metastatic and metastatic CRC groups, respectively. Protein-protein interaction analysis revealed that they were predominantly involved in immune responses, complement pathways, wound healing and coagulation. Of these, the levels of complement C9 (C9) was increased and fibronectin (FN1) was decreased in both CRC states in comparison to those of the healthy controls. Moreover, their levels detected by immunoblotting were validated in another independent cohort and the results were consistent with in the study cohort. Combination of CEA, a commercial CRC biomarker, with C9 and FN1 showed better diagnostic performance. Interestingly, predominant glycoforms associated with acetylneuraminic acid were obviously detected in alpha-2 macroglobulin, haptoglobin, alpha-1-acid glycoprotein 1, and complement C4-A of CRC patient groups. This glycoproteomic approach provides invaluable information of plasma proteome profiles of CRC patients and identification of CRC biomarker candidates.